HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lice Treatment Claims Require Tests On Humans, Not Just Bugs – NAD

This article was originally published in The Rose Sheet

Executive Summary

NAD rejects TyraTech’s argument that because its Vamousse homeopathic works on lice and not people, non-human studies are adequate substantiation. Vamousse advertising referred to challenger Sanofi Pasteur’s Sklice prescription lice spray as less effective and more risky to human health.

You may also be interested in...



US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name

National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.

Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Objection

Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.

Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Objection

Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.

Related Content

Latest News
UsernamePublicRestriction

Register

RS019564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel